Verastem, INC Schedule 13G passive stakes

Point72 Asset Management, along with Point72 Capital Advisors Inc. and Steven A. Cohen, has disclosed a 6.1% passive ownership stake in Verastem, Inc., totaling 3,338,419 shares.

OrbiMed Advisors LLC has filed an amended Schedule 13G, reporting a 5.6% beneficial ownership stake in Verastem, Inc.'s common stock as of March 31, 2025.

Nantahala Capital Management, along with Wilmot B. Harkey and Daniel Mack, has disclosed a 9.99% beneficial ownership stake in Verastem, Inc., totaling 5,459,278 shares, including shares acquirable via warrants.

RTW Investments, LP and its Managing Partner, Roderick Wong, M.D., have disclosed a passive beneficial ownership of 8.3% in Verastem, Inc.'s common stock as of March 31, 2025.

Balyasny Asset Management L.P. and its affiliates have filed an amended Schedule 13G, disclosing a beneficial ownership of 9.30% in Verastem Inc.'s common stock as of March 31, 2025.

Soleus Capital Management, L.P. and affiliated entities, including Guy Levy, have updated their beneficial ownership in Verastem, Inc. to an aggregate of 1.8% of the common stock as of March 31, 2025.

The Vanguard Group has filed an amended Schedule 13G, disclosing a 4.71% passive ownership stake in Verastem Inc. as of March 31, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 4.9% beneficial ownership stake in Verastem, Inc. as of March 31, 2025.

Barclays PLC has filed an amended Schedule 13G, revealing a passive beneficial ownership of 8.87% of Verastem Inc.'s common stock as of December 31, 2024.

Nantahala Capital Management, LLC, along with Wilmot B. Harkey and Daniel Mack, has disclosed a beneficial ownership of 9.99% in Verastem, Inc.'s common stock as of December 31, 2024.

A group of investment funds managed by Biotechnology Value Fund entities, including Mark N. Lampert, have disclosed a collective beneficial ownership of 9.99% in Verastem, Inc., primarily through common stock, convertible preferred stock, and warrants.

Alyeska Investment Group, L.P., along with its affiliates, reported a passive beneficial ownership of 2.1% of Verastem, Inc.'s common stock as of December 31, 2024.

Ramya Rao, associated with Barclays entities, has disclosed a passive beneficial ownership of 8.87% of Verastem Inc.'s common stock as of December 31, 2024.

Balyasny Asset Management and its affiliates have disclosed a passive beneficial ownership of 8.87% in Verastem Inc.'s common stock as of December 31, 2024.

Stonepine Capital Management, LLC and its affiliates have filed an amended Schedule 13G, disclosing a beneficial ownership of 4.8% of Verastem, Inc.'s common stock as of December 31, 2024.

Soleus Private Equity Fund III, L.P., Soleus Capital Master Fund, L.P., and related entities, along with Guy Levy, have filed an amended Schedule 13G disclosing a combined beneficial ownership of 7.3% of Verastem, Inc.'s common stock, including exercisable warrants.

The Vanguard Group has filed a Schedule 13G, revealing a 5.19% passive ownership stake in Verastem Inc. as of December 31, 2024.

AIGH Capital Management LLC and Orin Hirschman have reported a 6.1% beneficial ownership stake in Verastem, Inc., holding 2,717,827 shares of common stock as of December 31, 2024.